71
Participants
Start Date
July 11, 2017
Primary Completion Date
April 17, 2018
Study Completion Date
April 17, 2018
IVT aflibercept
IVT aflibercept \[2 mg/0.05 mL\]
Sham SC
sham SC
SC CLS-TA
CLS-TA \[4 mg/100 μL\] SC injection
The Johns Hopkins Wilmer Eye Institute, Baltimore
Western Carolina Retinal Associates, Asheville
Marietta Eye Clinic, Marietta
Retina Specialty Institute, Pensacola
Center for Retina and Macular Disease, Winter Haven
Sarasota Retina Institute, Sarasota
Retina and Vitrous Associates of Kentucky, Lexington
Midwest Eye Institute, Indianapolis
Texas Retina Associates, Dallas
Retina Consultants of Houston, The Woodlands
Valley Retina Institute, P.A., McAllen
Valley Retina Institute, McAllen
Austin Retina Associates, Austin
Retina Centers, PC, Tucson
Retina Institute of California, Palm Desert
California Retina Consultants, Bakersfield
Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View
Oregon Retina Institute, Medford
Retinal Consultants of Arizona and Retinal Research Institute, Phoenix
Retina Vitreous Medical Group Clinical Research, Beverly Hills
Retina Consultants San Diego, Poway
MedEye Associates, Miami
Emory Eye Center, Augusta
Cumberland Valley Retina Consultants, Hagerstown
Retina Associates of NJ, Teaneck
Black Hills Regional Eye Institute, Rapid City
Retina Research Institute of Texas, Abilene
Texas Retina Associates-Arlington, Arlington
Medical Center Ophthalmology Associates, San Antonio
Lead Sponsor
Clearside Biomedical, Inc.
INDUSTRY